AdAlta’s management team has been responsible for the development of the i-body technology platform, including the identification and pre-clinical development of the lead i-body drug candidate. AdAlta’s management team is focused on progressing the lung fibrosis therapy, AD-214, into the clinic.
MANAGING DIRECTOR & CEO
Sam is the founding CEO of AdAlta and has over fifteen years’ experience in business development and commercialisation of early stage scientific technologies. Prior to AdAlta, Sam was the Business Development Director at the Co-operative Research Centre for Diagnostics. Sam has also worked for the biotech start up companies Sensologix Inc and Nephrogenix Pty Ltd and at the University of Queensland’s technology commercialisation companies, Uniquest Pty Ltd and IMBcom Pty Ltd. Sam has a Bachelor of Science, a Masters of Intellectual Property Law and has completed the Australian Institute of Company Directors course.
Michael Foley PhD
Mick is the founding scientist of AdAlta and a key inventor of AdAlta’s lead i-body candidate AD-214. Upon completion of his PhD he was awarded a Wellcome Training Fellowship and worked at the Walter and Elisa Hall Institute. In 1995 Mick was awarded an ARC QEII Fellowship where he established the phage display of antibodies and peptide technology as a means of answering fundamental questions of immunity to infectious diseases. Mick is an internationally recognized leader in phage display, the technology used to screen the i-body library to identify new drug candidates. Having published over 70 scientific publications Mick has received funding from ARC, NHMRC and NIH (US).
Dallas Hartman PhD
Dallas is the Chief Operating Officer of AdAlta and has over 15 years experience in the biotechnology industry. Prior to joining AdAlta, Dallas was Vice President of Product Development at the NASDAQ listed biotechnology company Nexvet where he was responsible for scalable bioprocess development, formulation, stability, analytical characterisation and cell line development. Dallas worked at CSL for 14 years in a number of roles; most notably the Director of Analytical Biochemistry. Before moving to industry, Dallas undertook postdoctoral research at the University of Texas Southwestern Medical Center and the University of Melbourne where his worked was supported by fellowships from the Howard Hughes Medical Institute and the Australian Research Council. Dallas holds an MBA with specialist streams in finance and marketing and was Australasian Bioscience Business Manager for Biolab.